Compare AU
Compare RIIF vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are RIIF and CURE. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
RIIF | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 77 |
Median incremental investment | $0 | $640.11 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,190.74 |
Average age group | N/A | > 35 |
Key Summary
RIIF | CURE | |
|---|---|---|
Strategy | RIIF.AX was created on 2024-08-12 by Resolution Capital. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to achieve an annual total return that exceeds the total return of the Benchmark after fees on a rolling 3-year basis | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Resolution Gbl Listed Infra Fund - Active ETF (100 %) | Natera Inc (2.77 %) Alnylam Pharmaceuticals Inc (2.60 %) Vertex Pharmaceuticals Inc (2.58 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0 % | 0.45 % |
Key Summary
RIIF | CURE | |
|---|---|---|
Issuer | Resolution Capital | Global X |
Tracking index | FTSE Developed Core Infrastructure 50/50 Index - AUD - Benchmark TR Net Hedged | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0 % | 0.45 % |
Price | $1.105 | $41.60 |
Size | N/A | $30.458 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | 0.17 % | 4.24 % |
Market | ASX | ASX |
First listed date | 24/03/2025 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
RIIF | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 77 |
Median incremental investment | $0 | $640.11 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,190.74 |
Average age group | N/A | > 35 |
Pros and Cons
RIIF | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
RIIF | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |